Journal of High School Science

Optimizing Induced Pluripotent Stem Cells stability and reprogramming: bridging regenerative medicine and cancer treatment through proposed Antibody-Transcription Factor Conjugates

Agarwal S

Submitted: January 22, 2025, Revised: version 1, February 17, 2025
Accepted: February 19, 2025

Abstract
Induced Pluripotent Stem Cells (iPSCs) are stem cells derived from adult somatic cells with an equivalent pluripotency capability as embryonic stem cells (ESCs). The discovery of iPSCs was a significant breakthrough in the field of regenerative medicine, bypassing the ethical challenges surrounding ESCs while still having the ability to differentiate into various cell types for utilization in various clinical and research-related applications. Currently, iPSCs are being applied in disease modeling, drug screening, and tissue engineering, with future uses ranging from personalized medicine to multifactorial diseases. However, scientists are currently faced with several biological hurdles in the development of iPSC platforms. In particular, the current iPSC generation process is inefficient (high rate of incompletely reprogrammed cells), genetically unstable (high rate of tumorigenesis), immunogenic, and non-scalable. Recent attempts have tried to optimize the reprogramming with improved pluripotency and genetic integrity. Novel reprogramming factors and cultural conditions have been established, promising to mitigate these limitations. As iPSC technology advances in the area of regenerative medicine, new applications that are being developed indicate its possible applicability in the area of oncology. I propose that Antibody-Transcription Factor Conjugates (ATFCs) -along the lines of Antibody – Drug Conjugates - may be developed as a novel therapy that can reprogram cancer cells into pluripotent-like non-tumorigenic phenotypes and inhibit their malignant recurrence. By combining iPSC reprogramming principles and specific transcription factor targeting, ATFCs may offer another avenue for overcoming tumor resistance and improving cancer therapy. This review paper provides the current state of iPSC technology, the character and applications of iPSCs, and the limitations of their use. It also discusses recent advances in enhancing iPSC reprogramming efficiency, stability, and translational potential and how the suggested new approach such as ATFCs can further extend the range of iPSCs beyond that of regenerative medicine.

Keywords
Induced Pluripotent Stem Cells (iPSC), Yamanaka factors, Pluripotency, Genetic stability, Cellular reprogramming, Tumorigenesis, Antibody Transcription Factor Conjugates, Antibody Drug Conjugates, Drug resistance, Monoclonal antibody

Savya Agarwal, Dublin High School, 8151 Village Pkwy, Dublin, CA 94568, USA. savya.agr@gmail.com

1. Introduction

Induced pluripotent stem cells (iPSCs) represent one of the most pivotal advances in biomedical research and regenerative medicine. Discovered in 2006 by Shinya Yamanaka, iPSCs are induced by reprogramming differentiated somatic cells back to a pluripotent state (1), and then allowing them to mature into essentially any cell type in the human body. This technology opens new doors in personalized medicine, disease modeling and drug discovery, among others. iPSCs bypass the ethical concerns associated with embryonic stem cells, providing an alternative that does not require the destruction of embryos. iPSCs are now clinically used to differentiate and synthesize patient-specific tissues for transplantation via differentiation of specific cell types, lowering the susceptibility of immune rejection and opening new options for treating many diseases such as Parkinson's, diabetes, or spinal cord injury (2). In addition, iPSCs offer an opportunity to establish disease models and the cellular physiology of the passage of diseases in a controlled environment for drug testing (3). iPSCs are generated by the deliberate introduction of specific transcription factors, primarily the Yamanaka factors: OCT4, SOX2, KLF4, and c-MYC. These factors are typically delivered using viral vectors, which integrate the reprogramming genes into the somatic cell's DNA, reprogramming the cell into a pluripotent state (1). While this method has proven efficacious, it presents significant limitations. The current reprogramming process is notably suboptimal, with a success rate often below 1% of cells used, and the use of viral vectors carries the risk of genetic instability and the potential for risk of tumorigenesis, mainly due to the involvement of the c-MYC gene, a known oncogene (2). To improve the safety and efficiency of this process, alternative routes, including non-integrating methods and trends in the use of small molecules such as valproic acid, have been explored to enhance the efficiency and safety of the process (4). While promising, such strategies still need to reproducibly demonstrate their scalability and practical application within a clinical setting. Nevertheless, iPSCs remain a promising technology for the progression of regenerative medicine.

The ongoing advancement of iPSC research is critical to unlocking its full potential in research and clinical settings. Efforts to improve the efficiency of the reprogramming process would not only make iPSCs more accessible for therapeutic use, but also reduce the cost and time required to generate them. Moreover, by identifying novel gene combinations and optimizing reprogramming techniques, researchers can minimize the risk of genetic mutations and program long-term stability in iPSCs, making them safer and more practical for clinical application (5). Moreover, iPS cell-derived therapies have further potential for personalized medicine in generating patient-specific (autologous) cells and individualized treatment strategies, thereby mitigating the risk of immune rejection and improving clinical outcomes accordingly (2). This review paper will assess various iPSC generation strategies involving new reprogramming factors, gene composition, and innovative methodologies different from standard procedures. The intention is to provide a comprehensive account of the progress of iPSC technology and emphasize key areas that

may be furthered in research, specifically focusing on enhancing efficiency and broad clinical relevance. It will also focus on how such advancements could change the face of regenerative medicine, drug development, and related fields.

As part of an - as yet unpublished approach – I suggest the development of Antibody Transcription Factor Conjugates (ATFCs) – along the lines of Antibody- Drug Conjugates (ADCs) as a novel strategy that utilizes targeted antibody delivery to directly deliver reprogramming transcription factors to cancer cells. ATFCs could be designed to induce an iPSC-like state in tumor cells, hopefully circumventing limitations of current therapies such as drug resistance and off-target toxicity by effectively re-directing cell fate while simultaneously offering protection from re-malignancy. Recent evidence for transcription factor-mediated reprogramming (6) suggests that ATFCs should be explored as part of the next generation of cancer therapies.

2. What are iPSCs?

In the emergent category of stem cells, iPSCs are created by reprogramming matured and differentiated somatic cells into an embryonic-like state. In 2006, Shinya Yamanaka demonstrated that somatic cells could be reprogrammed back to a pluripotent state using specific transcription factors, thereby enabling applications like disease modeling and regenerative medicine without relying on embryonic stem cells (7). iPSCs can be generated directly from a patient's somatic source, avoiding ethical challenges and reducing the risk of immune rejection challenges during clinical applications (2). The ability to generate patient-specific stem cells also makes iPSCs a potential solution to personalized medicine for various diseases, including genetic disorders.

Cultivating iPSCs primarily involves isolating somatic cells, such as peripheral blood cells and fibroblasts, obtained through skin biopsies or blood samples (8). Fibroblasts are preferred due to their ease of access, availability, and robust growth in culture, making them suitable candidates for genetic manipulation (9). Post isolation, the somatic cells are exposed to a group of transcription factors called the Yamanaka factors—OCT4, SOX2, KLF4, and c-MYC (OSKM). These factors are important in reprogramming a somatic cell back to a pluripotent state by inducing the expression of genes necessary for stem cell maintanence (1). These transcription factors are delivered to cells via viral vectors carrying the OSKM cassette, such as lentivirus or retrovirus. These viral vectors allow for integrating the OSKM into the genome, allowing for iPSC reprogramming. Lentiviral constructs are commonly used due to their efficiency. However, the method is also associated with genetic instability because of the integration of foreign DNA into the host genome aside from mutation risk, which could increase the tumorigenesis rate, especially after the usage of c-MYC (4). c-MYC is responsible for cell proliferation. Overexpression, or dysregulation of this transcription factor can lead to uncontrolled cell proliferation leading to malignant tumor growth (10) or the inhibition of apoptosis suppressing programmed cell death, allowing for cells with DNA abnormalities to survive and continue to proliferate (11). These challenges are currently

being overcome through alternative delivery methods, such as non-integrating approaches with episomal plasmids and Sendai viruses that do not modify the host DNA so as to minimize genomic instability (3).



Figure 1. The Process of iPSC generation from somatic cell sources: 1. Somatic cell isolation: Somatic cells are often isolated from skin (fibroblasts) or blood (peripheral blood cells) biopsies **(1a)** from donors. The tissue is then treated with enzymes such as collagenase to break down the extracellular matrix (ECM), releasing fibroblasts from the connective tissues **(1b)** before isolation of the fibroblasts via centrifugation **(1c)**. **2. Cellular reprogramming:** Viral/ non-viral vectors introduce the transcription factors **(2a/2b)** (OCT4, c-MYC, KLF4, SOX2) to the host genome for stable expression. **(2c)** Culture is then placed in a specific reprogramming medium, such as Essential 8 or mTeSR1, supplemented with growth factors like basic fibroblast growth factor (bFGF) and grown on a feeder layer (e.g., irradiated mouse embryonic fibroblasts) or extracellular matrix coatings like Matrigel or laminin. This Culture is kept in a hypoxic environment to aid in reprogramming efficiency **(2d). 3. Colony Formation and Selection:** The somatic cells will lose their morphology over the next 2-3 weeks and start to form clusters of cells with high nuclear-to-cytoplasmic ratios **(3a).** Healthy uniform colonies resembling a morphology similar to embryonic stem cells (ESC) are then identified and expanded **(3b). 4. Verification of Pluripotency:** Test for markers for pluripotency (OCT4, SOX2, NANOG) in the cell colonies via immunology or qPCR test. 5. **Application/ Banking:** These cells may now be differentiated into different cell types (Ectoderm, Mesoderm, Endoderm, Germ Cells) **(5a.)** or may be cryopreserved for later use **(5b)** (L. Ho, 2024).

After the OSKM transcription factors are added, the cells are placed in a reprogramming medium that favors survival and reprogramms them to become pluripotent. The cells' somatic features are gradually lost. Over the same period, they acquire characteristics typical of stem cells, such as morphological changes and colony-formation abilities reminiscent of those made by ESCs (5). This is a critical reprogramming phase because such a reversal into the primitive state involves complex genetic and epigenetic modifications. The final step in the iPSC cultivation process is the verification of pluripotency. Researchers use various assays to confirm that the newly generated iPSCs exhibit key stem cell markers,

such as OCT4, SOX2, and NANOG. Additional tests involve assessing the cells' ability to differentiate into the three primary germ layers—ectoderm, mesoderm, and endoderm—a hallmark of true pluripotency (12). For a more comprehensive validation, iPSCs may be injected into immunodeficient mice to see if they form teratomas, a type of tumor containing cells from all three germ layers, further confirming their pluripotency (13).

Despite the significant advancements in iPSC technology, reprogramming is inefficient; reprogramming rates, often below 1% of total cells, and the risk of genetic mutations during cell manipulation significantly hinder their use in clinical settings (13). Therefore, this therapeutic and research modality must be more practical for large-scale use. New reprogramming factors and small molecules can be researched to improve the efficiency of iPSC generation without compromising genetic stability and subsequent oncogenesis (5). These should be channeled into optimizing the production process to make the iPSC production process safer and more amenable for broad clinical and research applications.

3. Current applications of iPSCs

iPSCs represent a new paradigm for regenerative medicine and biomedical research due to their enormous, unrealized potential for therapeutic and investigative use. Since their discovery, iPSCs have provided scientists a way to circumvent many ethical concerns associated with embryonic stem cells; since they reprogram somatic cells to a pluripotent state. This capability to make patient-specific cells enables personalized medicine applications and to construct complicated disease and drug testing models, ultimately advancing knowledge in disease mechanisms and treatments (14).

3.1 Clinical applications

iPSCs have proven to be a vector of promise, especially in regenerative medicine, since they can produce patient-compatible tissues, reducing the risk of immune rejection. One notable clinical use of iPSCs is in the treatment of Parkinson's disease, a neurodegenerative disorder marked by the loss of dopamine-producing neurons in the brain (15). Current treatments, such as dopamine replacement therapy, offer symptomatic and temporary alleviation but do not halt disease progression (16). The use of iPSC technology provides a solution by enabling the production of dopaminergic neurons directly from a patient's cells, which can then be grafted into the patient's brain to replace those lost. In 2017, Kikuchi et al. demonstrated that iPSC-derived dopaminergic progenitor cells were effective in a primate model of Parkinson's disease, where the cells integrated into host brain tissue, survived long-term, and improved motor function, setting a proof-of-concept for future human translation (17). Of note, some human clinical trials with iPSCs are in progress in Japan regarding the safety and efficacy for treatments of neurodegenerative disorders like Parkinson's disease. Results from these trials will provide significant information on the use of iPSC for the treatment of neurodegenerative disorders. BlueRock Therapeutics, Toronto, CA is conducting a clinical trial for the iPSC-based stem cell treatment of Parkinson's disease in the US and Canada. It met the primary endpoint in the Phase I clinical trial of

its iPSC-based dopaminergic neuronal therapy, Bemdaneprocel. The therapy demonstrated favorable safety and functional outcomes in patients with Parkinson's disease (18).

Apart from neurological, the other primary application of iPSCs is in treating Diabetes Mellitus, a chronic disease wherein the body either does not produce enough insulin or utilizes the insulin incorrectly, leading to high blood sugar levels. Traditional management includes insulin injections; however iPSC technology offers a novel approach to target the root cause of the disease by engineering insulin-producing pancreatic beta cells. For example, Vertex Pharmaceutical's cellular therapy VX-880 is based on iPSCs to produce insulin-secreting beta cells. Results of ongoing studies in Phase 1/2 have emerged, showing that patients regained insulin production with better blood glucose control, hence pointing toward possibilities of functional cure, thereby reducing or eliminating dependency on lifelong insulin therapy. (19). This is because using the patient's own cells minimizes the risk of immune rejection; a challenge faced by conventional organ and cell transplantation.

The other primary clinical application of iPSCs pertains to treating cardiovascular disease. Heart disease remains at the top of the list of the leading causes of death worldwide. Available treatments are symptom-oriented and involve medication, including lifestyle modification, and very rarely, heart transplantation. In this regard, iPSCs represent an alternative by producing patient-specific cardiomyocytes that could be used to repair damaged cardiac tissue. A study by Shiba et al. (20) successfully demonstrated the transplantation of iPSC derived cardiomyocytes into a primate model of myocardial infarction. These transplanted cells integrated with the host myocardium, improved heart function, and reduced arrhythmia risk, thus providing a good alternative for heart tissue regeneration. This can help alleviate the shortage of donor hearts and reduce risks associated with immune rejection, since the iPSC-derived cells are of autologous origin.

Other translational applications of iPSCs in fields such as ophthalmology have been realized in treating Age-related Macular Degeneration (AMD), the leading cause of blindness among elderly individuals (21). AMD involves the degeneration of Retinal Pigment Epithelial (RPE) cells, which enable vision. It has been clinically demonstrated that iPSC-derived RPE cells could be transplanted into the retina, replacing damaged cells with the hope of restoring lost vision. A clinical trial, the first of its kind in Japan, involved the transplantation of iPSC-derived RPE cells into an AMD patient and was the first use of iPSCs ever in a clinical setting. The surgical procedure was uncomplicated, with no adverse effects reported, and showed promise for the stabilization or amelioration of disease conditions in AMD. The success of such studies has encouraged further studies in applying iPSCs to other retinal diseases, hence underlining their application in ophthalmic regenerative medicine (22,23).

The wide range of successful applications of iPSCs in disease treatments in both *in vivo* and clinical trials demonstrate the significant contribution of iPSCs in medicine. iPSCs enable the production of any patient-specific

cells, amelioration of transplant-related immune rejection, and integration of regenerative medicine into treating a wide range of conditions.

Beyond the conventional clinical uses of monoclonal antibody drug conjugates, I propose that antibody mediated targeted delivery of reprogramming transcription factors using Antibody Transcription Factor Conjugates (ATFCs) – analogous to Antibody Drug Conjugates (ADCs) - may represent a paradigm shift in oncology. Exploiting the enhanced specificity offered by antibody-mediated targeting, ATFCs may be able to deliver preselected transcription factors specifically to cancer cells to induce a controlled shift toward an iPSC-like, non-tumorigenic phenotype. This reprogramming approach is not just aimed at "resetting" the oncogenic phenotype, but also at introducing engineered "fail-safe" states that inhibit re-differentiation into cancerous cell types. Extrapolating from available data on iPSC generation and targeted delivery systems, such an approach has the potential to circumvent conventional resistance mechanisms due to not causing outright cytotoxicity, but rather re-routing cell fate toward iPSC-like non-tumorigenic paths. The observations given, based on existing reprogramming and antibody technologies (24), indicate the potential of ATFCs to redefine cancer treatment paradigms by transforming cancer cells into stable and therapeutically controllable states. Some limitations include the ability of reprogramming tools, such as ATFCs, to induce a non-tumorigenic pluripotent iPSC-like state from differentiated tumor cells; and to perform this reprogramming *in vivo* in the absence of well defined culture composition and conditions.

3.2 Research applications

In addition to clinical applications, iPSCs are also creating new fields of research for applications in a research setting, where they are gaining ground in a new category of promising tools aimed toward understanding disease mechanisms, drug discovery, and genetic research. One of the most significant uses of iPSCs currently in research is for disease modeling. By generating patient-specific iPSCs, researchers can reprogram these cells into relevant cell types and study disease progression in a controlled laboratory environment. This is especially useful in studying diseases with complex cellular mechanisms, such as Amyotrophic Lateral Sclerosis (ALS). ALS is a neurodegenerative disease of motor neurons characterized by muscle weakness with progressive paralysis. Using iPSCs derived from ALS patients, such cells have been differentiated into motor neurons, exhibiting ALS-like features, including protein aggregation and cellular stress responses. Egawa et al. demonstrated disease-relevant phenotypes of ALS patients' iPSC-derived motor neurons, thus modeling ALS pathology and testing potential treatments. This approach offers the advantage of studying disease mechanisms in human cells directly and overcomes some of the limitations of animal models to further our understanding of complex conditions (25).

Besides disease modeling, iPSCs have also accelerated drug discovery and toxicology testing. Due to species differences, traditional drug testing depends on animal models that are

sub-optimum in predicting human responses. iPSC-derived cells ensure that drugs are tested on human cells that more closely approximate the target cells in the body. For example, iPSC-derived cardiomyocytes find broad applications in cardiotoxicity testing, a common side effect of many drugs. A study by Burridge et al. demonstrated that iPSC-derived cardiomyocytes could predict multiple drug cardiotoxicity, thus providing a safer and more accurate way of evaluating possible side effects. Application in this direction holds significant importance in the pharmaceutical industry, as it can minimize the cost and risks associated with drug development to discard drug candidates with potential for cardiotoxicity.

The benefits of iPSCs in genetic disorders research are different, enabling the development of disease models that accurately recapitulate patient-specific genetic mutations. For example, in the genetic disease Cystic Fibrosis (CF), caused by mutations in the CFTR gene, iPSCs have played a significant role in determining how such mutations affect cellular function. This makes it possible to understand the processes of disease and therapy because the differentiation of iPSCs from CF patients to airway epithelial cells allows research studies to investigate the impact of CFTR mutations at the molecular and cellular level. Additionally, iPSC-based models have enabled research into methods for the use of gene-editing techniques, including CRISPR-Cas9, to correct genetic mutations at the cellular level. Firth et al. demonstrated that gene editing in iPSC-derived airway epithelial cells rescued the CF phenotype and may provide a way for gene therapy in cystic fibrosis and other genetic disorders (24). This approach further develops our understanding of genetic diseases and how personalized therapies can be developed from the genetic background of a given individual (27,28).

Moreover, iPSCs have been a great asset in cancer biology research through their use as a model in studying the molecular mechanisms of tumorigenesis and in testing new therapeutic strategies. Cancer research with iPSCs has included reprogramming cancer cells back into a pluripotent state; thus, the capability of studying such cells differentiating and pathways involved in cancer progression is identified. These have been compared to iPSCs made from healthy cells, allowing researchers to determine how gene expression, cellular behavior, and drug response differ among iPSCs that differentiate into tumorigenic and non-tumorigenic cells. A similar approach in the future will enable the identification of new targets for drug development and personalized cancer therapies specific to the particular profile of an individual patient's tumor. In the context of the suggested ATFCs, the ability to reprogram differentiated tumor cells, back to an iPSC non-tumorigenic pluripotent phenotype is of particular importance.

iPSCs have revolutionized the clinical and research frontiers by offering flexible models that can be employed to provide insight into diseases, test new therapies, and work toward personalized treatments. Because they allow patient-specific cell generation, they will enable studies of complex conditions and facilitate the development of safer and more effective therapies. While there are still challenges regarding optimizing methods for

iPSC reprogramming and differentiation, ongoing research has enhanced their utility, adding to their applications, hence underscoring the potential that iPSCs have to reshape the future of medicine.

4. Challenges for extensive use of iPSCs

Despite their promise, iPSCs face several critical challenges that limit their use in clinical and research-based settings, primarily due to their scalability and safety. As mentioned previously, the success rate of the current reprogramming process is extremely low, at ~ 1%, due to a lack of efficient conversion techniques to transform somatic cells back into a pluripotent state (2). This already-low efficiency is further compounded by the extensive genetic and epigenetic alterations that cells must undergo during reprogramming. These can render the derived iPSCs unstable, sometimes with unpredictable behaviors. Moreover, the reliance upon viral vectors to deliver transcription factors, including the Yamanaka factors OCT4, SOX2, KLF4, and c-MYC, can disrupt the cell genome and lead to potentially oncogenic mutations.

One of the most essential restrictions of iPSCs concerns their genetic instability, which is ultimately linked to the increased risk of tumorigenesis. Many studies have shown that iPSCs can develop chromosomal aberrations, copy number variations, and mutations in key regulatory genes mainly related to cell proliferation and differentiation (29). The reprogramming process inflicts severe stress on the cell and places it in an environment highly conducive to DNA damage and subsequent mutations that may not be immediately evident. More specifically, genetic abnormalities induced by iPSCs pose a serious concern for clinical use, in which even minimal possibility of tumorigenic potential presents a hazard. One example is the use of the oncogene c-MYC to promote reprogramming efficiency. This is particularly problematic since this oncogene is well-known for promoting cell proliferation and can induce tumor formation *in vivo* (30).

Research is ongoing to reduce tumorigenesis risk of iPSCs, including the application of different reprogramming factors and of non-integrative methods, such as episomal plasmids and mRNA-based reprogramming. These alternative approaches have the potential to abrogate genomic integration and reduce the risk of insertional mutagenesis (31). However, most of these approaches exhibit lower reprogramming efficiencies, require repeated applications, and are technically challenging to scale for clinical use; thus, they currently represent only partial solutions (32).

iPSCs have epigenetic memory and the ability to retain genetic information, which affects their pluripotency and differentiation potential. This epigenetic memory is typically represented by residual DNA methylation and histone morphology characteristic of the cell's pre-origin state. For instance, iPSCs generated from fibroblasts would be more likely to differentiate into mesenchymal lineages and less likely other cell types, which limits their value for cross-lineage application. In several studies, this epigenetic memory creates a barrier to resetting iPSCs to their pluripotent state, further affecting their differentiation consistency and, thus, their therapeutic outcomes (33).

iPSCs have the potential to become immunogenic, making them incompatible with therapeutic applications when transplanted into patients post-differentiation for therapeutic application (34). Aberrant proteins produced by iPSCs can act as antigens, which the immune system recognizes as foreign (34). These cells might be rejected, even if they are self-derived. This has indeed been observed in animal models, where an immune response complicates the use of iPSCs in regenerative therapies, where immune tolerance is required for integration to succeed (36).

Some other limitations that diminish the utility of iPSC-derived cells include differentiation fidelity and functional maturity. It has been commonly noted that even with the use of optimal differentiation protocols, iPSC-derived cells do not possess complete functionality. For example, iPSC-derived cardiomyocytes commonly display immature electrophysiological properties and lack the nuanced structural organization characteristic of native heart muscle cells, thereby limiting their potential for cardiac therapies (37,38). Similarly, iPSC-derived neurons do not fully recapitulate mature neurons' connectivity and signaling properties, restricting their use in modeling neurodegenerative diseases and therapies (39). This lack of maturation across differentiated cell types limits the range of conditions that can effectively be modeled or treated with iPSCs (40).

In addition, quality control and scalability challenges remain significant obstacles for applications involving iPSCs due to high reprogramming efficiency and cellular behavior variability, leading to inconsistency among iPSC batches. The inconsistency has greatly limited the ability to reach standards required by the clinical demands and regulatory agencies concerning safety and efficacy. While whole-genome sequencing and karyotyping represent the most critical genetic and epigenetic screening means for determining mutational states in safeguarding the stability of cells, these methods are expensive and time-resource intensive and, therefore, hinder wide applicability (41). The failure to realize batch-to-batch consistency remains an ongoing challenge in iPSCs generation, especially in clinical applications where reproducibility and safety are paramount (42).

Overcoming these challenges is key to developing iPSC technology and realizing its full therapeutic benefits. Ongoing efforts in the research of safer methods for reprogramming, improvement of differentiation protocols, and genetic editing techniques such as CRISPR-Cas9 may attenuate these limitations. Until these problems are resolved, clinical utilization of iPSCs will be possible only with cautious follow-up and strict quality control to establish safety and efficiency for therapeutic use.

4.1 Reprogramming cancer cells to overcome genetic instability

While genetic instability represents a major caveat for iPSC-based regenerative medicine, directed reprogramming of cancer cells into iPSC-like states can paradoxically be exploited as a therapeutic strategy to change their genomic landscape and reduce tumor resistance. Cancer cells, particularly those of aggressive or treatment-resistant forms, harbor extensive chromosomal abnormalities, mutations in key regulatory genes, and

epigenetic dysregulation that drive tumor expansion and resistance to conventional therapies (43). Rather than aiming for the elimination of such cells, another strategy may involve reprogramming such cells into a controlled, pluripotent-like state, such that subsequent differentiation results in the formation of non-malignant, functional cellular phenotypes.

Antibody-Transcription Factor Conjugates (ATFCs) may provide a novel approach to achieving this outcome through targeted delivery of reprogramming factors to cancer cells. Unlike conventional iPSC generation, which involves viral vector integration, ATFCs can conjugate transcription factors such as OCT4, SOX2, KLF4, and NANOG onto monoclonal antibodies that can target the surface markers on cancer cells for controlled dedifferentiation without subsequent re-transformation into malignancies. Although recent advances do not specifically address this idea (24), such progress renders it into the realm of possibility.

Reprogramming the cancer cells to a more stable phenotype may also diminish their capacity to develop resistance. Transcriptional modulation and epigenetic reprogramming research indicate that epigenetic changes in DNA methylation and histone acetylation patterns can erase oncogenic memory, thereby locking and redirecting the cells into an ordered differentiation pathway. Co-administration of ATFC therapy alongside epigenetic modulators, like DNMT inhibitors and histone deacetylase inhibitors (HDACi), might directly allow manipulation of cancer cell fate, potentially inducing them to transform into cellular types no longer capable of sustaining malignancy (6).

A common problem with standard cancer treatments, like chemotherapy and radiation, is that they impose huge selective pressures that permit only the most resilient cancer subpopulations to remain viable. This fuels tumor evolution and makes follow-on therapies less effective. ATFC therapy can flip the script from cancer cell killing to cancer cell reprogramming and, potentially, reduce the emergence of therapy-resistant clones. In contrast to cytotoxic drugs, which generate more mutations via DNA damage, reprogramming mechanisms directly engage the cell's transcriptional and epigenetic landscape to dictate a non-cancerous identity (44).

One of the principal challenges with reprogramming cancer cells to induced pluripotent stem cell-like states is the danger of reverting to an oncogenic phenotype. This can be potentially alleviated by the inclusion of reprogramming factors with genetic protection, i.e., CRISPR gene editing, aimed at eliminating oncogenic drivers before differentiation (45). Should this approach prove successful, it could radically alter cancer therapy by reprogramming malignant tumors into functionally stable, non-dividing cellular phenotypes as opposed to requiring cytotoxic treatments.

To prevent uncontrolled pluripotency and improve therapeutic effectiveness, Pre-Patterned Reprogramming ATFCs can be engineered to directly guide cancer cells into functional, lineage-restricted progenitor cells. Instead of triggering a general state of

pluripotency, ATFCs can be engineered to co-transduce reprogramming factors and differentiation signals for a specific lineage. As an instance, in glioblastoma therapy, ATFCs can transduce SOX2 and OLIG2, guiding oligodendrocyte differentiation rather than inducing uncontrolled pluripotent states. Furthermore, bioengineered synthetic niches could be applied to enhance differentiation fidelity. Reprogrammed cells can be implanted in customized 3D extracellular matrix (ECM) scaffolds, which provide spatial and biochemical signals controlling differentiation into stable, non-dividing cell types such as fibroblasts or astrocytes. These ECM-based guidance systems ensure that ATFC-reprogrammed cells develop into functionally meaningful tissues rather than uncontrolled states, reducing the risks of iPSC-based treatments.

Although the idea of reprogramming cancer cells by ATFC therapy is new and as yet unreported in the public domain, it presents an attractive alternative to traditional oncology concepts. If successfully developed, this method can minimize therapy-induced resistance by inhibiting the development of mutational escape variants, decrease the dependency on cytotoxic drugs to ameliorate long-term side effects, and create a more manageable strategy for tumor control by inducing differentiation instead of destruction.

To enhance the specificity of Antibody-Transcription Factor Conjugates (ATFCs), a dual-antigen target approach may be employed. Existing monoclonal antibodies currently in use for anticancer therapy mostly target a single marker, which may also be expressed by non-oncogenically transformed cells, thus making them responsible for off-target effects. A more precise approach would be to design ATFCs with dual-binding specificity, such that one antibody arm is directed against a surface marker on cancer cells (e.g., CD133, EpCAM), while the other is targeted against a tumor microenvironment-specific protein (e.g., VEGFR or integrins). This confines ATFC internalization to the malignant cells of the tumor microenvironment and curtails undesirable reprogramming of the normal cells. Alternatively, similar to Logic gates and circuits in CAR-T therapy, ATFC's can be designed to reprogram only those cells which are mutants or oncogenically transformed.

Second, CRISPR-activated ATFCs (CRISPRa-ATFCs) can potentially transform reprogramming by activation of endogenous pluripotency genes instead of delivery of external transcription factors. Existing ATFCs introduce exogenous transcription factors with the risk of insertional mutagenesis. In contrast, CRISPR systems transiently increase endogenous OCT4, NANOG, and SOX2 in cancer cells in a way that enables controlled and safe reprogramming. Such an intervention mitigates the genomic instability risk while ensuring conversion only for those cells that need the correct epigenetic landscape into an iPSC-like cell state.

5. Novel techniques to optimize and stabilize current processes

For making iPSC technology feasible both clinically and in research, efficiency in reprogramming and genetic stability are essential. Chemical reprogramming is currently utilized by substituting traditional transcription

factors with small molecules. Small molecules, such as histone deacetylase and GSK3 inhibitors, can invoke chromatin remodeling and subsequently enhance cellular receptivity to reprogramming. Hou et al. demonstrated that a cocktail of small molecules would improve the reprogramming efficiency in somatic cells without the need for viral vectors or chemicals that introduce oncogene integration and promote open chromatin structure. This small molecule cocktail would favor the transition toward a pluripotent state without purturbing the genetic configuration (46). Among RNA-based approaches, mRNA reprogramming has also demonstrated excellent safety and efficiency. The transient, non-integrative mRNA approach minimizes the possibility of permanent genetic alteration or mutagenesis, a significant advantage over viral vectors. Warren et al. showed that iPSCs were reprogrammed more efficiently using the mRNA approach rather than the viral toolkit and more safely because of the lower probability of mutagenesis. The approach showed a higher compliance with clinical-grade standards, thus presenting it as a safer candidate for iPSC applications (47). CRISPR/Cas9 gene editing has improved mutation correction and iPSC genome stabilization. CRISPR minimizes the instability that would otherwise arise from reprogramming by precisely targeting and correcting genetic mutations. Studies by Howden et al. showed that targeted gene correction enhances the viability and functionality of iPSCs without introducing off-target effects, advancing the prospects for therapeutic applications (48). Researchers used advanced methods to 'erase' this memory and achieve a more uniform pluripotent state to overcome the epigenetic memory challenge in iPSCs. One of the promising approaches involves treatment with histone methyltransferase inhibitors targeting those enzymes responsible for maintaining lineage-specific epigenetic marks. The inhibitors of such enzymes, for example, of H3K9 methyltransferase, improve resetting of the memory of a somatic cell and, consequently, improve the propensity to differentiate the iPSC. Indeed, by inhibiting histone methylation morphology related to the previous lineage of the cell, a complete reversion to pluripotency can be achieved.

Many strategies aim to change DNA methylation extent to facilitate epigenetic reprogramming. Cells have been treated with agents such as 5-azacytidine to remove residual DNA methylation from the somatic origin by reducing the levels of DNMTs, hence aiding in homogenous reprogramming.

Of equal importance, the challenge of immunogenicity does arise, whereby even the iPSCs derived from a patient's cells can provoke immune responses. Reasons suggested included the genetic and epigenetic changes during the reprogramming process that eventually lead to the expression of aberrant proteins. The immune system recognizes these aberrant proteins as foreign. So far, modulation of the iPSC immune response pathway has been a promising strategy. Genetic modifications in knocking out specific genes implicated in immunogenicity resulted in decreased expression of major histocompatibility complex molecules and in subsequently diminished immune rejection.

Additionally, the CRISPR/Cas9 gene silencing technique was used as a more precise approach so as to induce minimal immune responses in iPSC-derived cells by silencing genes that conferred immunogenicity. Others included preconditioning iPSCs using immuno-modulatory agents, such as interferon-gamma inhibitors, to prevent immune system activation after transplantation. Recent investigations have shown that such pre-exposure significantly enhances integration and promotes residency within the host tissue of iPSC-derived cells, with a marked enhancement in therapeutic applicability to using iPSCs for regenerative medicine. These steps in immunogenicity management further contribute to safer uses for the iPSCs and, by extension, an increase in feasibility toward clinical usage.

Ensuring differentiation fidelity and enhancing functional maturity within iPSC-derived cells will be essential touchstones in improving therapeutic reliability. One of the critical challenges in iPSC differentiation is that the cells often retain immature characteristics that limit their use in specific applications. For example, iPSC-derived cardiomyocytes and neurons usually express immature structural and electrophysiological properties that reduce their value in disease modeling and regenerative therapies. Because of this, recent strategies have focused on cellular environment optimization to drive functional maturation. For instance, 3D culture systems that are more biomimetic of the natural extracellular matrix have been developed, providing supportive environments encouraging cellular organization and maturation. Chen et al. reported improved cardiomyocyte maturation with better contractile function and electrophysiological properties for iPSCs cultured in 3D matrices (49).

Moreover, the culture of iPSCs with mature cell types or within organoid structures has provided higher orders of differentiation and functional maturity. This system utilizes complex cellular interactions to determine cell differentiation fates by providing lacking cues that enhance developmental processes in iPSC-derived cells. Co-culture of neuronal cells with astrocytes increased synaptic connectivity and signal transmission, an important feature when modeling neurodegenerative diseases with iPSCs. Co-culture techniques mimic the physiological environment and reduce the gap in translating iPSC-derived cells to their *in vivo* counterparts.

Another strategy involves the manipulation of specific signaling pathways that are known to turn on during the process of maturation. For example, Wnt and Notch signaling pathways have long been recognized to drive the differentiation and maturation of most cell types. Induction of these pathways during differentiation often enhances functional properties and makes iPSC-derived cells more native-like. Inhibition of aberrant Wnt/β-catenin signaling has been shown to rescue functional defects in iPSC-derived cardiomyocytes, improving their structural and electrophysiological properties and advancing their suitability for clinical applications (50).

Clinical application suitability is increased by using bioengineered scaffolds and biomaterials, which can mimic or approximate the same mechanical and chemical properties as natural

tissues. These scaffolds present a physical framework, impregnated with biochemical cues, that direct the cells to maturity. Biomimetic scaffolds of iPSC hepatic cells improve cellular organization for the realization of liver-specific functions and the acquisition of metabolic competence for an improved model for studies on diseases of the liver and their treatment. Such biomaterials can also provide a controlled release of growth factors and cytokines, becoming an integral part of the supportive environment that enhances cellular differentiation and maturation.

Among the preconditions for the wide availability of these cells for extended clinical and research uses are increasing scalability and quality control in their production. Highly variable reprogramming efficiency, along with cellular heterogeneity between different batches of iPSCs, poses a significant barrier to the reproducibility of the results. One of the approaches to overcome scalability is by automating the culture and differentiation of iPSCs. Development in this regard involves automated bioreactor systems to produce large-scale iPSCs, which provide controlled conditions for better consistency and reduced contamination. For example, microcarrier-based bioreactors represent a scalable system through an increase in the surface area for cell growth, hence enabling the production of larger quantities of iPSCs without compromising quality (51). These systems improve cell production efficiency and represent a pathway to the standardization of iPSC generation, which is considered a prerequisite for the therapeutic application of these cells.

Moreover, developing new genomic and epigenomic screening methodologies further enhances quality control in iPSCs. Most traditional screening methodologies, including whole-genome sequencing and karyotyping, are relatively expensive and time-consuming. For that reason, there has been a concerted effort to search for the development of rapid and less invasive screening protocols, such as digital PCR, capable of detecting mutations and genetic abnormalities with high sensitivity. This technology allows the reprogramming Process to monitor the quality continuously and only allows genetically stable iPSCs to be added to further downstream applications. Innovations like this in quality control reduce possibilities for adverse outcomes since cells must meet strict safety standards before therapeutic use.

Another paradigm-changing use in the quality monitoring of iPSCs and prediction of differentiation is through machine learning and artificial intelligence. Machine learning algorithms, for instance, can predict pluripotency and differentiation potential from single-cell RNA sequencing. This, therefore, provides new opportunities to identify top-quality cell lines in production processes earlier. AI and ML algorithms can reduce batch-to-batch variability to enhance the consistency and quality of iPSC production. For example, AI-abled organoids exist that automate processes for cell cultures, thus reducing human operational errors, leading to more reliable and reproducible results. Moreover, AI and ML can be used to analyze the most complicated datasets, thus increasing the reproducibility and reliability of iPSC-derived organoid models. Such advances could

include the power of AI and ML in identifying low-quality or highly mutated cell lines, further improving batch-to-batch consistency (52). Implementing AI in production stages increases scalability for iPSCs by reducing required human supervision and offers a path to high-throughput, reproducible manufacture of iPSCs. In turn, exploration is done on adopting good manufacturing practices and GMP-compliant protocols prescribed by regulatory authorities to ensure the uniformity and safety of the product. AI and ML algorithms can address everything ranging from quality control at raw material input to final testing of the final product. Adhering to GMP criteria will enable researchers to develop lines that are not only safer but reproducible, fit for therapeutic use, more so in a clinical setting where safety for the patients is the primary concern.

5.1 Engineering ATFCs for selective cancer cell reprogramming and stable differentiation

The biggest challenge in induced pluripotent stem cell (iPSC) technology is efficient reprogramming without genetic instability. In comparison to conventional reprogramming with a focus on converting rate optimization and reduction of oncogenic risk, a new approach is based on the utilization of Antibody-Transcription Factor Conjugates (ATFCs) as a targeted approach to reprogramming cancer cells.

ATFCs introduce a new approach that selectively reprograms cancer cells into an induced pluripotent stem cell (iPSC))----like state while also preventing tumorigenic relapse. In contrast to traditional small-molecule-based reprogramming methods, ATFCs can utilize monoclonal antibodies linked to transcription factors (e.g., OCT4, SOX2, KLF4, and NANOG) that target specific cancer cell markers like EGFR, HER2, or CD133. This activity ensures that only cancer cells are selectively reprogrammed in a controlled manner, thus preventing off-target effects in normal tissues (24). As described earlier, gene-logic gates or circuits can also be built into ATFCs such that reprogramming is specific only to tumor cells.

One of the significant drawbacks of iPSC-based reprogramming is the possibility of genomic instability and the risk of uncontrolled cell growth. To mitigate such drawbacks, ATFC therapy can be merged with CRISPR-mediated genetic suppressors of oncogenic pathways before differentiation. Through the addition of self-inactivating control loops, transcription factors from ATFCs would only be transiently expressed and hence avoid extended pluripotent stages that could increase the possibility of tumor formation (45).

Furthermore, agents that facilitate epigenetic reprogramming, including DNA methylation inhibitors (such as 5-azacytidine) and histone deacetylase inhibitors (HDACi), may be utilized following the reprogramming process to eliminate oncogenic memory and guide the differentiation of reprogrammed cells towards stable, non-malignant lineages. Research suggests that the combination of epigenetic modulators with induced pluripotent stem cell (iPSC) reprogramming can effectively hinder cancer cells from reverting to their malignant phenotype, thereby presenting a feasible therapeutic approach.

Prevention of reprogrammed cancer cells from reverting to a cancerous condition is one of the key challenges in ATFC therapy. To address this, Self-Terminating ATFCs (Smart ATFCs) could be designed with built-in genetic safety switches. One of the approaches involves the introduction of inducible apoptotic caspases that remain inactivated until oncogenic markers such as MYC, KRAS, or BCL2 are again re-expressed. When a reprogrammed cell begins to acquire cancerous traits, the engineered caspase system is triggered, which leads to programmed cell death.

MicroRNA mediated reprogramming surveillance is another fail-safe process. MicroRNAs that are tumor suppressive (e.g., miR-34 and let-7) can be co-delivered with ATFCs, persistently monitoring cell conditions. Upon a drift in microRNA composition toward an oncogenic signature, reprogramming is shut down, and differentiation is stably guided toward a non-malignant lineage. Dynamic regulation bars unlimited cell proliferation and maintains therapeutic effectiveness.

A major obstacle in iPSC differentiation is the attainment of functional maturity. The majority of iPSC-derived cells exhibit immature structural and electrophysiological properties, limiting their use in clinical applications. To enhance differentiation outcomes, ATFC treatment can include the use of 3D biomimetic scaffolds with similarities to the extracellular matrix (ECM) to provide architectural and biochemical signals to guide reprogrammed cells into specific functional lineages. Research has determined that ECM environments based on hydrogel significantly improve differentiation fidelity by enhancing cellular organization and mechanotransduction signaling (49). An advantage of *in vivo* programming is that all the cellular cues and extracellular matrix achitecture is already present during cellular dedifferentiation or differentiation.

For enhancing the clinical utility of ATFC-based iPSC reprogramming, it is possible to utilize machine learning and artificial intelligence (AI) models in predicting differentiation results and deciphering single-cell transcriptomics. AI-powered systems can facilitate the detection of aberrant cell states early during reprogramming, thereby excluding unstable or incompletely reprogrammed cells from subsequent applications (6).

Through the incorporation of specific reprogramming mechanisms, genetic safeguards, epigenetic reinforcement, biomimetic differentiation cues, and AI-enhanced quality control, ATFCs may offer a comprehensively controlled and clinically applicable strategy for reprogramming cancer cells. This innovation signals a paradigm shift in cancer treatment from tumor ablation to the molecular reprogramming of tumors into functional, benign cellular structures. If successfully developed, ATFC therapy would reduce therapy-induced resistance, reduce the need for cytotoxic therapies, and enhance the safety of reprogramming-based therapies for regenerative medicine.

6. Emerging reprogramming techniques

Scientists are investigating new reprogramming techniques to advance the iPSC technology, improving efficiency and safety. One promising direction involves using a non-

integrative Sendai virus that is cytoplasmic and, hence, does not integrate into the host genome, reducing the risk of mutagenesis (53). The high reprogramming efficiency of the Sendai virus also involves fewer genetic changes. Application yields have been more stable in iPSC lines with less oncogenic risk. The advantages of using the Sendai virus were described by Fusaki et al. This method retains the advantages of virus-based reprogramming but without the genomic hazards associated with other viral vectors; hence it is suitable for applications requiring a high degree of genetic fidelity (54).

Other non-viral vectors, in addition to the Sendai virus methods, are also gaining traction. Episomal plasmid vectors that remain extrachromosomal are increasingly used due to their safety profile and ability to achieve high reprogramming efficiency. Okita et al., demonstrated that episomal vectors require more extended expression than mRNA reprogramming but yield stable iPSC lines with low mutagenesis potential (55). This method is both efficient and scalable, providing a means for producing safer batches of iPSCs at reduced cost.

Gene-editing technologies, mainly those enabling CRISPR activation, are also being researched for selective activation of endogenous pluripotency genes without introducing exogenous sequences. In this respect, CRISPRa would allow targeting of specific cellular reprogramming genes, hence enhancing the efficiency and stability of reprogramming. Methodologies based on CRISPRa increase the success rates of reprogramming, thus offering one more exciting opportunity to develop precise and nuanced production of iPSCs (56). Harnessing the host cell's genetic machinery, CRISPRa promises a procedure to minimize risks of both mutation and epigenetic variation for safer clinical applications.

6.1 CRISPR-mediated control of transcription factors to enhance ATFC therapy

New developments in CRISPR-based gene regulation provide new opportunities to improve ATFC treatment by augmenting its precision, safety, and efficacy. Whereas conventional CRISPR-Cas9 systems induce double-stranded breaks for gene editing, a safer approach is to utilize CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi) strategies that regulate gene expression without making changes in the underlying genomic sequences.

The combination of catalytically inactive Cas9 (dCas9) with transcriptional activators or repressors enables specific upregulation of endogenous pluripotency genes in targeted cells without the requirement of external transcription factor introduction. This is a potential modification for ATFC therapy to improve the reprogramming of cancer cells as well as circumvent the risks of viral vector-based approaches. For instance, ATFCs containing CRISPRa-regulated transcription factors can selectively activate chosen endogenous iPSC-associated genes (OCT4, SOX2, KLF4, NANOG) in cancer cells, allowing controlled reprogramming without introducing foreign DNA (57).

To additionally enhance differentiation fidelity and prevent tumorigenic relapse, CRISPRi-

mediated repression can also suppress oncogenes (e.g., MYC, BCL2, KRAS) at the same time to prevent reprogrammed cells from undergoing tumorigenic transformation. This approach provides greater control over the activity of transcription factors, reducing variability and potential risks of ATFC-based reprogramming.

Furthermore, CRISPRa-programmed ATFCs can be used with epigenetic regulators like DNMTi and HDACi to erase oncogenic epigenetic memory and induce stable reprogramming into non-malignant cell lineages. Pre-treatment of cancer cells with reprogramming-favoring agents before treating them with ATFCs can further enhance safety and efficacy (58).

One of the cornerstones of ATFC therapy approach is to cause tumor quiescence instead of destruction. Unlike most cancer therapies, which rely on cytotoxic pathways that give rise to therapy-resistant clones, quiescence-inducing ATFCs have the potential to reprogram cancer cells to a stable dormant-like state that prevents further tumor growth. The approach exploits transcriptional regulation of key pathways such as p53 and RB to manoeuvre differentiated progression toward a non-malignant phenotype without triggering apoptosis. Such an approach can prevent therapy-resistant relapse.

Furthermore, ATFCs may be combined with epigenetic rewiring therapies to restore immune recognition of reprogrammed cells. Rogue reprogrammed cells are prone to escape from immune detection by T-cell exhaustion and immunosuppressive signals in the tumor microenvironment. By modulation of MHC-I expression and restoration of antigen presentation, ATFC-reprogrammed rogue cells may maintain immunogenicity and serve as natural cancer vaccine-like targets. This may serve as another advantage of ATFC treatment. Rather than directly killing cancer cells, ATFC treatment can potentially transform any tumorigenic reprogrammed cells into auto-targeting immunogenic reservoirs, reducing recurrence and increasing long-term remission.

Aside from transcriptional regulation, CRISPR-based synthetic genetic circuits could be incorporated into ATFC systems to engineer self-sustaining reprogramming. By engineering ATFCs to activate pluripotency genes only upon specific tumor microenvironmental inputs, off-target reprogramming in non-tumorous tissues could be minimized, further improving the specificity and therapeutic safety of ATFC treatment.

The advances in CRISPR-mediated gene regulation, when coupled with ATFC-based cancer reprogramming, may herald a paradigm change in the field of transcription factor engineering. This advance allows a precise, tunable, and clinically applicable strategy to control the destiny of cancer cells with reduced oncogenic hazards. Much more work remains to be done to realize the potential of this proposed therapy.

7. Clinical and research implications of optimized iPSC techniques

The latest round of optimizations to iPSC derivation, stability, and scalability has immense implications at the bench and clinic. Novel, safer, more active reprogramming

techniques might significantly change personalized medicine, especially regenerative therapies, from treating spinal cord injuries to heart disease and neurodegenerative disorders. This allows the derivation of functionally mature and genetically stable iPSCs, hence providing insights into regenerative medicine for developing cell-based therapies that can integrate into the patient's tissues and minimize the risk of rejection or other adverse effects.

Optimized iPSCs allow researchers to more faithfully recapitulate disease conditions in disease modeling, thus enabling drug testing and the development of novel treatments. The greater maturity of iPSC-derived cells allows the capture of active disease phenotypes and improvement of *in vitro* predictive validity of drug responses. For example, iPSC-derived neurons and cardiomyocytes with improved maturation profiles already serve as models for Alzheimer's and cardiovascular diseases, respectively, affording unprecedented insights into disease mechanisms and treatments. As quality control continues to become more stringent, iPSC models will assume an even more central role in high-throughput drug screening, rapidly accelerating the process of finding new drugs.

These improvements further anchor the rationale behind iPSC biobanking: to store well-characterized, high-quality iPSC lines for future research and clinical use. Such biobanks, which follow strict quality criteria and uniform protocols for reprogramming, may provide a starting point for personalized therapies-specific treatments matched to a patient's genetic and diseased profile. Biobanks containing GMP-compliant iPSC lines would allow clinicians to access reliable and safe cell sources, reducing production times for patient-specific iPSCs and further enabling the feasibility of personalized regenerative medicine on a much larger scale.

Apart from regenerative medicine, the developments also open up new avenues in cancer treatment, particularly through Antibody-Transcription Factor Conjugate (ATFC) therapy. Traditional monoclonal antibody therapies have existed for a while to combat cancer cells based on primarily immune-mediated cytotoxicity. However, the greatest challenge with oncology has been the development of therapy-refractory tumor populations that acquire mechanisms of immune evasion and resistance to treatment. ATFC therapy provides a novel path for diverting cancer cells towards a reprogrammed, non-malignant phenotype instead of their total elimination. Through targeted delivery of transcription factors, ATFCs can potentially bypass selective pressures underlying monoclonal antibody therapy resistance and thus transform the treatment of high-grade malignancies. It is a paradigm shift in the field of oncology, with transcriptional reprogramming as a viable alternative to cytotoxic and immune-based therapies.

8. Conclusion

The integration of Antibody-Transcription Factor Conjugates (ATFCs) as an innovative therapeutic strategy enhances the clinical applicability of induced pluripotent stem cell (iPSC) technology, presenting fresh opportunities for cancer therapies that extend beyond conventional cytotoxic methods. The capacity to accurately reprogram cancer cells

into stable, non-malignant phenotypes represents a significant transformation in oncology, where transcriptional reprogramming has the potential to alleviate tumor resistance and serve as an alternative to treatments centered on immune targeting or chemotherapy. Such an approach, as discussed herein, would bridge regenerative medicine and oncology, additionally demonstrating the therapeutic flexibility of iPSCs in clinical settings.

These findings also pave the way for the future optimization of iPSC culture techniques so that reprogramming efficiency, gene stability, and safety are enhanced for clinical regenerative applications and disease models. Traditional iPSC reprogramming is confronted by a plethora of problems including low efficiency and gene instability, limiting its clinical applicability. However, by optimizing reprogramming conditions and merging state-of-the-art epigenetic modulation approaches, gene mutation risk can be circumvented, thus enabling patient-specific therapy for diseases such as Parkinson's disease, diabetes, and cardiovascular disease. Genetically more stable iPSCs will reduce immune rejection rates, enabling hitherto impossible transplantations due to host incompatibility.

Beyond personalized cell therapies, iPSC optimization also has significant potential for drug discovery, toxicology, and disease modeling. The ability to generate more functionally mature and physiologically relevant cell types may enhance high-throughput drug screening, enhancing the predictive validity of drug responses. Such developments may also reduce the reliance on animal models, enabling human-derived cell systems that more accurately recapitulate pathological mechanisms in neurodegenerative, cardiovascular, and metabolic diseases.

Further advancement of iPSC studies, particularly the integration of CRISPR-dependent genome editing, can bring personalized medicine to a new level. By enabling precise genetic correction at the cellular level, CRISPR can address disease-causing mutations before differentiation, offering a preemptive approach to combat genetic disease. Furthermore, bioengineering innovations and AI-driven quality control will be key to the development of scalable and standardized iPSC lines, accelerating the establishment of clinical-grade iPSC biobanks for specific genetic profiles. The integration of Self-Terminating ATFCs, Pre-Patterned Reprogramming, and Quiescence-Inducing Strategies represents a new frontier in cancer therapy. These advances move away from traditional cytotoxic treatments, offering a reprogramming-based modality that stabilizes, as opposed to eliminating, malignant cells. With the potential of dual-antigen ATFCs, CRISPRa-mediated gene expression, and immune-sensitization mechanisms, ATFC therapy could be a paradigm shift in oncology —a paradigm in which cancer cells are directed toward a non-proliferative, non-malignant fate rather than being put under selection pressure to develop resistance. Future studies in synthetic niche engineering, metabolic control of reprogrammed cells, and AI-driven monitoring of differentiation fidelity will be essential in streamlining this technology for clinical translation and use in precision oncology. Such biobanks would facilitate the

generation of patient-specific treatments, with pre-characterized, genetically stable cell lines ready to use therapeutically.

As iPSC technologies evolve, the prospects for regenerative medicine and disease treatment expand exponentially. iPSC optimization, coupled with the suggested novel application like ATFCs, have the potential to transform the landscape of modern medicine by enabling highly customized, patient-specific therapies. Standardization, customization, and synergy with cutting-edge genomic and bioengineering techniques will be critical in bringing these techniques to the clinic. With the continued advancement of these techniques, iPSC-based therapies can alter treatment paradigms, ushering in medical advances across disciplines and making previously impossible therapies achievable.

Acknowledgments

I would like to thank Ms. Lananha Ho from the Department of Biomedical Engineering at the University of Rochester for providing me with the guidance and knowledge I needed to complete this paper successfully. I would also like to thank the anonymous reviewers at JHSS for providing me with a platform to share my work.

9. Abbreviations

ATFC: Antibody Transcription Factor Conjugate, OCT4: Octamer Binding Transcription factor 4, SOX2: SeX determining region Y-box 2, KLF4: Kruppel Like Factor 4, c-MYC: Cellular MYeloCytomatosis oncogene, CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats, p53: Tumor Protein p53, RB: RetinoBlastoma1, miR-34: microRNA-34A, Let-7: Lethal-7, NANOG: NANOG Homeobox transcription factor (Tir Na Nog, the land of the ever-young in Celtic mythology), Bcl2: B Cell Leukemia/Lymphomo-2 protein, KRAS: Kristen RAt Sarcoma viral oncogene homolog, MHC-I: Major Histocompatibility Complex Class I, EGFR: Epidermal Growth Factor Receptor HER2: Human Epidermal growth factor Receptor-2, CD133: Cluster of Differentiation 133, Wnt: Wingless related iNTegration site, Notch: Neurogenic lOcus noTCH homolog protein 1, Cas9: Caspase 9, GSK3: Glycogen Synthase Kinase 3, EpCAM: Epithelial Cellular Adhesion Molecule

10. References

1. Li, Y., Shen, Z., Shelat, H., Geng, Y. J. (2013). Reprogramming somatic cells to pluripotency: a fresh look at Yamanaka's model. *Cell cycle*, 12(23), 3594–3598. https://doi.org/10.4161/cc.26952

2. Takahashi, K., Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell,* 126(4), 663–676. https://doi.org/10.1016/j.cell.2006.07.024

3. Liu, G., David, B. T., Trawczynski, M., Fessler, R. G. (2020). Advances in pluripotent stem cells: History, mechanisms, technologies, and applications. *Stem Cell Reviews and Reports,* 16(1), 3–32. https://doi.org/10.1007/s12015-019-09935-x

4. Lin, T., Wu, S. (2015). Reprogramming with Small Molecules instead of Exogenous Transcription Factors. *Stem Cells International*, 2015, 794632. https://doi.org/10.1155/2015/794632

5. Al Abbar, A., Ngai, S. C., Nograles, N., Alhaji, S. Y., Abdullah, S. (2020). Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy. *BioResearch open access*, 9(1), 121–136. https://doi.org/10.1089/biores.2019.0046

6. Zhao, J., Fang, W., Gao, Y., Chen, J., Wang, G., Gu, J. (2025). iPSC-derived exosomes as amphotericin B carriers: a promising approach to combat cryptococcal meningitis. *Frontiers in Microbiology*, 16. https://doi.org/10.3389/fmicb.2025.1531425

7. Farrar, S. (2016). Characterization and analysis of human umbilical cord perivascular cells. *Thesis*, The University of Manchester, Division of Cardiovascular sciences, Machester, UK. https://core.ac.uk/download/186348454.pdf

8. Re, S., Dogan, A. A., Ben-Shachar, D., Berger, G., Werling, A. M., Walitza, S., Grünblatt, E. (2018). Improved Generation of Induced Pluripotent Stem Cells From Hair Derived Keratinocytes - A Tool to Study Neurodevelopmental Disorders as ADHD. *Frontiers in cellular neuroscience*, 12, 321. https://doi.org/10.3389/fncel.2018.00321

9. Drozd, A. M., Walczak, M. P., Piaskowski, S., Stoczynska-Fidelus, E., Rieske, P., Grzela, D. P. (2015). Human iPSCs from cells of fibroblastic and epithelial origin cells can be generated using the oriP/EBNA-1 episomal reprogramming system. *Stem cell research & therapy*, 6(1), 122. https://doi.org/10.1186/s13287-015-0112-3

10. Elbadawy, M., Usui, T., Yamawaki, H., Sasaki, K. (2019). Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer. *International journal of molecular sciences*, 20(9), 2340. https://doi.org/10.3390/ijms20092340

11. Dang, C. V. (2012). MYC on the path to cancer. *Cell,* 149(1), 22–35. https://doi.org/10.1016/j.cell.2012.03.003

12. Shafa, M., Yang, F., Fellner, T., Rao, M. S., Baghbaderani, B. A. (2018). Human-induced pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant

Process Differentiate Into Clinically Relevant Cells From Three Germ Layers. *Frontiers in medicine*, 5, 69. https://doi.org/10.3389/fmed.2018.00069

13. Wesselschmidt R. L. (2011). The teratoma assay: an *in vivo* assessment of pluripotency. *Methods in molecular biology*, 767, 231–241. https://doi.org/10.1007/978-1-61779-201-4_17

14. Ebert, A. D., Liang, P., Wu, J. C. (2012). Induced pluripotent stem cells as a disease modeling and drug screening platform. *Journal of Cardiovascular Pharmacology*, 60(4), 408–416. https://doi.org/10.1097/FJC.0b013e318247f642

15. Parkinson's News Today. (2023). IntelGenx and Karolinska reach agreement to advance Parkinson's montelukast study. *Parkinson's News Today*. https://parkinsonsnewstoday.com/news/intelgenx-karolinska-reach-agreement-parkinsons-montelukast-study/

16. Gouda, N. A., Elkamhawy, A., Cho, J. (2022). Emerging Therapeutic Strategies for Parkinson's Disease and Future Prospects: A 2021 Update. *Biomedicines*, 10(2), 371. https://doi.org/10.3390/biomedicines10020371

17. Kikuchi, T., Morizane, A., Doi, D., Magotani, H., Onoe, H., Hayashi, T., et al. (2017). Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model. *Nature,* 548(7669), 592–596. https://doi.org/10.1038/nature23664

18. BlueRock Therapeutics. (2024). BlueRock's Phase I Study with Bemdaneprocel in Patients with Parkinson's Disease Meets Primary Endpoint. *BlueRock Therapeutics.* https://bluerocktx.com

19. Vertex Pharmaceuticals. (2024). Vertex Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 in Patients with Type 1 Diabetes. *Vertex Pharmaceuticals.* https://vrtx.com

20. Shiba, Y., Fernandes, S., Zhu, W., Filice, D., Muskheli, V., Kim, J., et al. (2016). Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. *Nature,* 489(7415), 322–325. https://doi.org/10.1038/nature11317

21. Kirkeby, A., Main, H., Carpenter, M. (2025). Pluripotent stem-cell-derived therapies in clinical trials: a 2025 update. *Cell Stem Cell*, 32(1), P10-37. https://doi.org/10.1016/j.stem.2024.12.005

22. Zhang, H., Su, B., Jiao, L., Xu, Z. H., Zhang, C. J., Nie, J., et al. (2021). Transplantation of GMP-grade human iPSC-derived retinal pigment epithelial cells in rodent model: the first pre-

clinical study for safety and efficacy in China. *Annals of translational medicine*, 9(3), 245. https://doi.org/10.21037/atm-20-4707

23. Al-Shamekh, S., Goldberg, J. L. (2014). Retinal repair with induced pluripotent stem cells. *Translational research: The Journal of Laboratory and Clinical Medicine*, 163(4), 377–386. https://doi.org/10.1016/j.trsl.2013.11.002

24. FierceBiotech. (2023). Science fiction becomes reality: New George Church-founded biotech raises $75M for cell therapy platform. https://www.fiercebiotech.com/biotech/science-fiction-reality-new-george-church-founded-biotech-raises-75m-cell-therapy-platform

25. Egawa, N., Kitaoka, S., Tsukita, K., Naitoh, M., Takahashi, K., Yamamoto, T., et al. (2012). Drug screening for ALS using patient-specific induced pluripotent stem cells. *Science Translational Medicine,* 4(145), 145ra104. https://doi.org/10.1126/scitranslmed.3004052

26. Pankratov, A. (2013). Design and Optimization of a Sequence-Specific Chimeric DNA-Binding Domain for the Discrimination of Single Nucleotide Polymorphisms. Worcester Polytechnic Institute. https://digital.wpi.edu/concern/student_works/cj82k8650?locale=en

27. Chun, Y. S., Byun, K., Lee, B. (2011). Induced pluripotent stem cells and personalized medicine: current progress and future perspectives. *Anatomy & cell biology*, 44(4), 245–255. https://doi.org/10.5115/acb.2011.44.4.245

28. Schnabel, L. V., Abratte, C. M., Schimenti, J. C., Southard, T. L., Fortier, L. A. (2012). Genetic background affects induced pluripotent stem cell generation. *Stem cell research & therapy*, 3(4), 30. https://doi.org/10.1186/scrt121

29. Poetsch, M. S., Strano, A., Guan, K. (2022). Human Induced Pluripotent Stem Cells: From Cell Origin, Genomic Stability, and Epigenetic Memory to Translational Medicine. *Stem cells*, 40(6), 546–555. https://doi.org/10.1093/stmcls/sxac020

30. Lee, A. S., Tang, C., Rao, M. S., Weissman, I. L., Wu, J. C. (2013). Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. *Nature medicine*, 19(8), 998–1004. https://doi.org/10.1038/nm.3267

31. Lin, Y. C., Ku, C. C., Wuputra, K., Liu, C. J., Wu, D. C., Satou, M., Mitsui, Y., Saito, S., Yokoyama, K. K. (2024). Possible Strategies to Reduce the Tumorigenic Risk of Reprogrammed Normal and Cancer Cells. *International journal of molecular sciences*, 25(10), 5177. https://doi.org/10.3390/ijms25105177

32. Moy, A. B., Kamath, A., Ternes, S., Kamath, J. (2023). The Challenges to Advancing Induced Pluripotent Stem Cell-Dependent Cell Replacement Therapy. *Medical research archives*, 11(11), 4784. https://doi.org/10.18103/mra.v11i11.4784

33. Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., et al. (2010). Epigenetic memory in induced pluripotent stem cells. *Nature*, 467(7313), 285–290. https://doi.org/10.1038/nature09342

34. Liang, G., Zhang, Y. (2013). Genetic and epigenetic variations in iPSCs: potential causes and implications for application. *Cell stem cell*, 13(2), 149–159. https://doi.org/10.1016/j.stem.2013.07.001

35. Damon Runyon Cancer Research Foundation. (n.d.). How pancreatic cancer survivors shed light on the immune system. *Damon Runyon Cancer Research Foundation.* https://www.damonrunyon.org/our-impact/new-discoveries/entries/6961/How%20pancreatic%20cancer%20survivors%20shed%20light%20on%20the%20immune%20system

36. Pearl, J. I., Kean, L. S., Davis, M. M., Wu, J. C. (2012). Pluripotent stem cells: immune to the immune system? *Science translational medicine*, 4(164), 164ps25. https://doi.org/10.1126/scitranslmed.3005090

37. Garg, P., Garg, V., Shrestha, R., Sanguinetti, M. C., Kamp, T. J., Wu, J. C. (2018). Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as Models for Cardiac Channelopathies: A Primer for Non-Electrophysiologists. *Circulation Research*, 123(2), 224–243. https://doi.org/10.1161/CIRCRESAHA.118.311209

38. Burnett, S. D., Blanchette, A. D., Chiu, W. A., Rusyn, I. (2021). Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an *in vitro* model in toxicology: strengths and weaknesses for hazard identification and risk characterization. *Expert opinion on drug metabolism & toxicology*, 17(8), 887–902. https://doi.org/10.1080/17425255.2021.1894122

39. Valadez-Barba, V., Cota-Coronado, A., Hernández-Pérez, O. R., Lugo-Fabres, P. H., Padilla-Camberos, E., Díaz, N. F., Díaz-Martínez, N. E. (2020). iPSC for modeling neurodegenerative disorders. *Regenerative therapy*, 15, 332–339. https://doi.org/10.1016/j.reth.2020.11.006

40. Al Khleifat, A., Iacoangeli, A., Shatunov, A., Fang, T., Sproviero, W., Jones, A. R., et al. (2019). Telomere length is greater in ALS than in controls: a whole genome sequencing study. *Amyotrophic lateral sclerosis & frontotemporal degeneration*, 20(3-4), 229–234. https://doi.org/10.1080/21678421.2019.1586951

41. Christensen, K. D., Dukhovny, D., Siebert, U., Green, R. C. (2015). Assessing the Costs and Cost-Effectiveness of Genomic Sequencing. *Journal of personalized medicine*, 5(4), 470–486. https://doi.org/10.3390/jpm5040470

42. Neofytou, E., O'Brien, C. G., Couture, L. A., Wu, J. C. (2015). Hurdles to clinical translation of human induced pluripotent stem cells. *The Journal of Clinical Investigation*, 125(7), 2551–2557. https://doi.org/10.1172/JCI80575

43. Ng, A.H.M., Khoshakhlagh, P., Rojo Arias, J.E. et al. A comprehensive library of human transcription factors for cell fate engineering. *Nat Biotechnol* 39, 510–519 (2021). https://doi.org/10.1038/s41587-020-0742-6

44. Kim, J., Lopes, M., Pereira, C.-F. (2025). Attenuating cancer cell memory and discovering cancer biomarkers with cellular reprogramming—An interview with Dr. Jungsun Kim. *Cellular Reprogramming*, 27(1). https://doi.org/10.1089/cell.2025.0007

45. Fraunhofer, J.-P., Young, W. B., Pykett, M. J. (2018). Compositions and methods for modulating CD47 expression (Patent No. WO2018049382A1).

46. Hou, P., Li, Y., Zhang, X., Liu, C., Guan, J., Li, H., et al. (2013). Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. *Science (New York, N.Y.)*, 341(6146), 651–654. https://doi.org/10.1126/science.1239278

47. Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y. H., Li, H., Lau, F., et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. *Cell stem cell*, 7(5), 618–630. https://doi.org/10.1016/j.stem.2010.08.012

48. Howden, S. E., Maufort, J. P., Duffin, B. M., Elefanty, A. G., Stanley, E. G., Thomson, J. A. (2015). Simultaneous Reprogramming and Gene Correction of Patient Fibroblasts. *Stem cell reports*, 5(6), 1109–1118. https://doi.org/10.1016/j.stemcr.2015.10.009

49. Chen H., Maia-Joca R., Ong C., DiSilvestre D, Tomaselli G., Reich D (2020). Enhancement of human iPSC-derived cardiomyocyte maturation by chemical conditioning in a 3D environment. *Journal of Molecular and Cellular Cardiology*, 138, 1 - 11. https://www.jmcc-online.com/article/S0022-2828(19)30200-7/abstract?utm_source=chatgpt.com

50. Cai, D., Wang, X., Sun, Y., Fan, H., Zhou, J., Yang, Z., et al. (2023). Patient-specific iPSC-derived cardiomyocytes reveal aberrant activation of Wnt/β-catenin signaling in SCN5A-related

Brugada syndrome. *Stem cell research & therapy*, 14(1), 241. https://doi.org/10.1186/s13287-023-03477-3

51. Eicke, D., Baigger, A., Schulze, K., Latham, S. L., Halloin, C., Zweigerdt, R., Guzman, C. A., Blasczyk, R., Figueiredo, C. (2018). Large-scale production of megakaryocytes in microcarrier-supported stirred suspension bioreactors. *Scientific reports*, 8(1), 10146. https://doi.org/10.1038/s41598-018-28459-x

52. Bai, L., Wu, Y., Li, G., Zhang, W., Zhang, H., Su, J. (2023). AI-enabled organoids: Construction, analysis, and application. *Bioactive materials*, 31, 525–548. https://doi.org/10.1016/j.bioactmat.2023.09.005

53. SU Support. (n.d.). Non-viral vectors vs. viral vectors in gene therapy. SU Support. https://www.susupport.com/knowledge/biopharmaceutical-products/drug-delivery/viral-vectors-viral-vectors-gene-therapy

54. Fusaki, N., Ban, H., Nishiyama, A., Saeki, K., Hasegawa, M. (2009). Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. *Proceedings of the Japan Academy. Series B, Physical and biological sciences*, 85(8), 348–362. https://doi.org/10.2183/pjab.85.348

55. Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., et al. (2011). A more efficient method to generate integration-free human iPS cells. *Nature Methods*, 8(5), 409-412.https://doi.org/10.1038/nmeth.1591

56. Weltner, J., Balboa, D., Katayama, S. et al. Human pluripotent reprogramming with CRISPR activators. *Nat Commun* 9, 2643 (2018). https://doi.org/10.1038/s41467-018-05067-x

57. Martinez-Escobar, A., Luna-Callejas, B., Ramón-Gallegos, E. (2021). CRISPR-dCas9-based artificial transcription factors to improve the efficacy of cancer treatment with drug repurposing: Proposal for future research. *Frontiers in Oncology*, 10. https://doi.org/10.3389/fonc.2020.604948

58. Zhao, J., Fang, W., Gao, Y., Chen, J., Wang, G., Gu, J. (2025). iPSC-derived exosomes as amphotericin B carriers: a promising approach to combat cryptococcal meningitis. *Frontiers in Microbiology*, 16. https://doi.org/10.3389/fmicb.2025.1531425